This invention relates to compounds, compositions, and methods useful for
modulating the expression and activity of NF-kappa-B by RNA interference
(RNAi) using small nucleic acid molecules, such as short interfering
nucleic acid (siNA), short interfering RNA (siRNA) and double-stranded
RNA (dsRNA). Furthermore the invention provides methods for preventing,
treating or alleviating NF-kappa-B dependent diseases whereby NF-kappa-B
is believed to play a role in the pathogenesis of a disease in a subject,
preferably a human, by administration of a therapeutic effective and in a
pharmacologically accepted form, the siRNA compounds of the invention.